Literature DB >> 23404221

CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer.

Seiya Saito1, Hirohisa Okabe, Masayuki Watanabe, Takatsugu Ishimoto, Masaaki Iwatsuki, Yoshifumi Baba, Youhei Tanaka, Junji Kurashige, Yuji Miyamoto, Hideo Baba.   

Abstract

CD44 standard isoform (CD44s) is a cancer stem cell marker in many tumors, and is one of the CD44 isoforms.CD44v6 has been reported to correlate with tumor progression and poor prognosis in colorectal cancer. However, the relevance of CD44s and CD44v6 to epithelial-mesenchymal transition (EMT) remains unclear. Immunohistochemistry was performed to investigate the clinical importance of CD44s and CD44v6 and their relevance to EMT in 113 patients with stage II/III colorectal cancer treated by curative resection. The relevance of CD44v6 knockdown to the phenotype of colon cancer cells was examined using small interfering RNA (siRNA) specific for CD44v6 in vitro. CD44v6 expression showed a significant inverse correlation with E-cadherin expression (P=0.0007) and a positive correlation with vimentin expression (P=0.0096). A multivariate analysis showed that high CD44v6 expression was an independent poor prognostic factor for disease-free survival (P=0.01, HR=3.05) and overall survival (P=0.025, HR=3.16). The clinical significance and the relevance of CD44s expression to EMT markers was noted to a lesser extent compared to CD44v6 expression. The knockdown of CD44v6 decreased vimentin expression, cell invasion and HGF-induced cell migration, but conferred only a slight effect on E-cadherin expression in colon cancer cells (HCT116 and LoVo). CD44v6 is related to poor outcome of patients with colorectal cancer via upregulation of the mesenchymal phenotype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404221     DOI: 10.3892/or.2013.2273

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  39 in total

Review 1.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

2.  CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression.

Authors:  L H Zhao; Q L Lin; J Wei; Y L Huai; K J Wang; H Y Yan
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  Hypoxia-induced alternative splicing in human diseases: the pledge, the turn, and the prestige.

Authors:  Subhashis Natua; Cheemala Ashok; Sanjeev Shukla
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

Review 4.  Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.

Authors:  Nidhi Jyotsana; Michael Heuser
Journal:  Expert Opin Ther Targets       Date:  2017-12-20       Impact factor: 6.902

5.  Intratumoral heterogeneity of CD44v6 in rectal cancer.

Authors:  H-G Liu; L Lv; H Shen
Journal:  Clin Transl Oncol       Date:  2016-08-23       Impact factor: 3.405

Review 6.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

7.  Combined preoperative CEA and CD44v6 improves prognostic value in patients with stage I and stage II colorectal cancer.

Authors:  L Chen; B Jiang; Z Wang; M Liu; H Yang; J Xing; C Zhang; Z Yao; N Zhang; M Cui; X Su
Journal:  Clin Transl Oncol       Date:  2013-07-17       Impact factor: 3.405

8.  Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer.

Authors:  Nhi Huynh; Arthur Shulkes; Graham Baldwin; Hong He
Journal:  Cancer Biol Ther       Date:  2016-06-03       Impact factor: 4.742

Review 9.  Cancer stem cells in human digestive tract malignancies.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Morvarid Saeinasab
Journal:  Tumour Biol       Date:  2015-10-07

10.  Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.

Authors:  Reihaneh Alsadat Mahmoudian; Maryam Lotfi Gharaie; Mohammad Reza Abbaszadegan; Ali Alasti; Mohammad Mahdi Forghanifard; Atena Mansouri; Mehran Gholamin
Journal:  Mol Cell Biochem       Date:  2021-02-19       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.